Biodexa Pharmaceuticals (NASDAQ:BDRX) Stock Set to Reverse Split on Monday, October 26th

Shares of Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) are scheduled to reverse split on the morning of Monday, October 26th. The 1-8 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, October 25th.

Biodexa Pharmaceuticals Price Performance

NASDAQ:BDRX opened at $0.46 on Friday. Biodexa Pharmaceuticals has a 1-year low of $0.34 and a 1-year high of $44.70. The business’s 50-day moving average price is $0.89 and its two-hundred day moving average price is $2.25.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded shares of Biodexa Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research report on Wednesday. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, Biodexa Pharmaceuticals presently has an average rating of “Sell”.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals plc, formerly known as Midatech Pharma plc, is a biopharmaceutical company focused on developing medicines for diseases with significant unmet medical needs. The company’s work has centered on oncology, rare diseases and conditions that are difficult to treat with conventional drug-delivery methods.

Biodexa’s development programs have included MTX110, a proprietary aqueous formulation of panobinostat being investigated for direct administration into brain tumors, including diffuse intrinsic pontine glioma.